Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2017

View Archived Issues

Serum ST2 found to be a predictor of mortality in HIV-infected patients

Letermovir shows promising phase III results in HCT patients for CMV infection prevention

AURA-LV study of voclosporin in lupus nephritis meets 48-week remission endpoints

Achaogen offers overview of R&D programs and introduces new antibiotic clinical candidate

Series B funding at Omeicos to support new clinical program for OMT-28

BeiGene initiates pivotal study of BGB-3111 in Chinese patients with mantel cell lymphoma

Pivotal Chinese study of fruquintinib in colorectal cancer meets endpoints

Boehringer Ingelheim and Vanderbilt University expand collaboration

RAGE identified as therapeutic target in COPD

Synthon and Sanquin enter immuno-oncology collaboration and license agreement

Otsuka Pharmaceutical agrees to acquire Neurovance

Phase I results for ODM-204 in mCRPC patients show promise

Scynexis holds initiation of clinical studies of intravenous SCY-078 following FDA communication

Carnitine levels indicate risk of myocardial infarction in HIV-infected adults

Sanofi and MedImmune sign agreement to develop and commercialize MEDI-8897

Bellus Health and NEOMED Institute enter exclusive worldwide license agreement for BLU-5937

Sosei submits marketing authorization application in Japan for SO-1105 for oropharyngeal candidiasis

Phase III study of ataluren in nonsense mutation cystic fibrosis does not meet endpoints

Integral Molecular and Integrated BioTherapeutics sign collaborate vaccine discovery agreement

Glucocorticoid receptor expression predicts poor outcomes in mCRPC treated with ARSi

NEONC Technologies' NEO-212 given U.S. orphan status for intracranial metastases from breast cancer

PBI-4050 granted U.S. orphan drug designation for the treatment of Alstrom syndrome

Zhejiang Hisun Pharmaceutical describes novel FGFR inhibitors

Karyopharm Therapeutics patents PAK and/or NAMPT modulators

Karus Therapeutics discovers novel PI3K-beta and PI3K-gamma inhibitors

Changzhou Jiekai Pharmatech describes new ERK2 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...